. » First country specific recommendation in Europe » Key to foster product awareness for Intercell's vaccine to prevent Japanese Encephalitis Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information Subtitle: ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report 02.03.2010 Vienna (Austria), March 2, 2010 - Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 11.02.2010 » Initial results from a first-in-man Phase I study indicate safety and immunogenicity of the Streptococcus ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Wien (euro adhoc) - _ » Phase II pilot efficacy trial - placebo controlled field study to evaluate efficacy and enterotoxigenic E. coli (ETEC) incidence of ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Capital measures Vienna, December 30, 2009 (euro adhoc) - Following the completion of a capital increase of 900,000 shares, which were sold to GlaxoSmithKline Biologicals SA at an issue price of EUR 31.21 per share, and admission of the ...
- » First Phase III trial towards pediatric label extension for IXIARO®/JESPECT® preventing Japanese Encephalitis (JE) in travelers to endemic countries » Important development step towards making IXIARO/JESPECT available to children Corporate news transmitted by euro adhoc. The issuer/originator ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 16.12.2009 » Pseudomonas vaccine: Study in intensive care patients to investigate immunogenicity and safety of a Pseudomonas aeruginosa vaccine and to assess Pseudomonas ...
Stock Option Program Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information Subtitle: Stock Option Program Vienna (euro adhoc) - Pursuant to Section 4.11 of the Articles of Association in accordance with Section 159 ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. New Products 11.12.2009 Vienna (Austria) / London (UK), December 11, 2009 - Intercell and GlaxoSmithKline Biologicals SA (GSK) today announced an ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 9-month report 09.11.2009 » Progress on Japanese Encephalitis vaccine (IXIARO®/JESPECT®) business and global reach - approval in Canada obtained - Phase III study start in India for JE-vaccine ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. New Products Vienna, Austria, October 30, 2009 (euro adhoc) - Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO®, the company's ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 14.10.2009 » Placebo controlled field study to confirm vaccine efficacy in travelers to Guatemala and Mexico Vienna ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 6-month report 17.08.2009 Vienna (Austria) August 17, 2009 - Today, Intercell AG (VSE: ICLL) announced its financial results for Q2 and H1 ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies Wien (euro adhoc) - Since 2002, the shareholders meeting of INTERCELL AG has issued stock options on a regular basis to members of the management board, the supervisory board ...
» Expanded Guidelines to include availability of IXIARO® vaccine for Japanese Encephalitis » IXIARO now available in the U.S. for travelers to Asia, military personnel, others at high risk regardless of the length of visit Corporate news transmitted by euro adhoc. The issuer/originator is solely ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 28.05.2009 » Phase II clinical trial investigating the effectiveness of Intercell´s Vaccine Enhancement (VE) Patch in ...
(Stock Options to Members of the Supervisory Board) Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/Announcement Wien (euro adhoc) - - 1. General 1.1 The shareholders´ meeting to be held on 19 June 2009 shall ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 3-month report 11.05.2009 » First product sales of Japanese Encephalitis vaccine in Australia » Solid revenue growth and profitability expected for full year 2009 » Excellent progress in vaccine ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 08.05.2009 » Exclusive, multi-year contract executed by Intercell and U.S. Department of Defense for purchase of ...
» ADRs to provide a more convenient way for US investors to invest in Intercell » Each ADR will represent one Intercell AG ordinary share » Intercell's shares are listed and will continue to trade on the Vienna Stock Exchange (VSE) - ADRs are expected to be quoted on the OTCQX International market under the symbol "INRLY" Corporate news transmitted by ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. research Vienna (Austria) and Gaithersburg (USA), April 29, 2009 (euro adhoc) - Intercell AG (VSE: ICLL) today informed regulators, partners and other parties involved in its planned pivotal Phase III efficacy study for the ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 07.04.2009 » Initiation of a first-in-man Phase I clinical trial in healthy subjects » Study aims to obtain safety and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 02.04.2009 » European Commission grants marketing authorization for Intercell´s IXIARO®, the first licensed vaccine against Japanese Encephalitis for travelers and ...
» U.S. FDA (Food and Drug Administration) approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for adult travelers and military personnel » Success of Intercell's new JE vaccine is a result of an excellent collaboration between Intercell and the Walter Reed Army ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. New Products 30.03.2009 » U.S. FDA approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for travelers and military personnel » Commercial product launch ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 06.03.2009 Vienna, Austria, March 6, 2009 - Intercell AG (VSE: ICLL) today announced that Reinhard Kandera has been appointed as Chief Financial Officer (CFO). In his new ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 9-month report 02.03.2009 » Increased profitability and strong financial position for full-year 2008 » Excellent progress in late-stage pipeline products » Vaccine to prevent Japanese ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. new product Wien (euro adhoc) - Vienna, Austria, January 23, 2009 - Intercell AG (VSE: ICLL) today announced that the Australian Therapeutic Goods Administration (TGA) granted product approval for ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. cooperations Wien (euro adhoc) - Vienna (Austria), January 19, 2009 - Intercell AG (VSE: ICLL) announced it has signed an exclusive agreement with Novartis AG for the marketing and distribution of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 29.12.2008 » Initiation of a Phase II clinical trial in mechanically ventilated intensive care patients - Study aims to investigate immunogenicity and safety in ...